Your browser doesn't support javascript.
loading
The Cognitive and Behavioural Effects of Perampanel in Children with Neurodevelopmental Disorders: A Systematic Review.
Scorrano, Giovanna; Lattanzi, Simona; Salpietro, Vincenzo; Giannini, Cosimo; Chiarelli, Francesco; Matricardi, Sara.
Afiliação
  • Scorrano G; Department of Paediatrics, University of Chieti-Pescara, 66100 Chieti, Italy.
  • Lattanzi S; Department of Experimental and Clinical Medicine, Neurological Clinic, Marche Polytechnic University, 60020 Ancona, Italy.
  • Salpietro V; Department of Neuromuscular Disease, UCL Institute of Neurology, University College London, London WC1N 3BG, UK.
  • Giannini C; Department of Biotechnological and Applied Clinical Sciences (DISCAB), University of L'Aquila, 67100 L'Aquila, Italy.
  • Chiarelli F; Department of Paediatrics, University of Chieti-Pescara, 66100 Chieti, Italy.
  • Matricardi S; Department of Paediatrics, University of Chieti-Pescara, 66100 Chieti, Italy.
J Clin Med ; 13(2)2024 Jan 10.
Article em En | MEDLINE | ID: mdl-38256507
ABSTRACT
In children and adolescents with epilepsy, neurodevelopmental comorbidities can impair the quality of life more than seizures. The aim of this review was to evaluate the cognitive and behavioural effects of perampanel (PER) in the paediatric population. We performed a systematic search of the literature, selecting studies published in English including children and adolescents with epilepsy treated with PER. Cognitive and behavioural outcomes were assessed through validated neuropsychological standardised scales. Eighteen studies involving 3563 paediatric patients were included. Perampanel did not impair general cognitive functions and visuospatial skills, whereas a slight improvement in verbal memory and a decline in attentional power were detected. In adolescents with refractory epilepsies, high doses and/or rapid titration of PER and an underlying psychiatric disorder were risk factors for developing or worsening psychiatric outcomes such as anger, aggressiveness, and irritability. Data on children and adolescents treated with new antiseizure medications are scant, and neuropsychiatric effects are tricky to be detected during developmental age. According to the currently available evidence, PER showed an overall favourable risk-benefit profile. Pharmacodynamics, co-administration of other antiseizure medications, and family and personal history of neuropsychiatric disorders should be considered before PER treatment.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Risk_factors_studies / Systematic_reviews Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Risk_factors_studies / Systematic_reviews Idioma: En Ano de publicação: 2024 Tipo de documento: Article